<DOC>
	<DOCNO>NCT01286441</DOCNO>
	<brief_summary>Nonclinical study show sandalwood oil anti-inflammatory , anti-fungal , antiviral , anti-bacterial activity . Previous clinical study show East Indian Sandalwood oil promising treatment common wart adult child . The primary objective study evaluate efficacy safety 10 % , 20 % , 30 % East Indian Sandalwood Oil ( EISO ) ointment compare ointment placebo administer twice daily ( bid ) 12 week treatment common wart ( Verruca vulgaris ) .</brief_summary>
	<brief_title>A Phase 2 Trial East Indian Sandalwood Oil Treatment Common Warts ( Verruca Vulgaris )</brief_title>
	<detailed_description />
	<mesh_term>Warts</mesh_term>
	<criteria>1 . Are male female , 18 year age old enrollment ; 2 . Have 2 10 common wart ( Verruca vulgaris ) treat within single 5 cmby5 cm contiguous area ( treatment area ) ; 3 . The treatment area locate anywhere body except follow prohibit area : eye area ( include eyelid ) , lip , mouth cavity , nasal cavity , inner ear , palm hand , sol foot , anogenital area ; 4 . The total surface area wart treat â‰¤600 mm2 ; 5 . If female childbearing potential , negative urine pregnancy test Screening Randomization/Day 1 , willing use effective contraception study ( ie , oral , implanted , injectable contraceptive , intrauterine device ( IUD ) , diaphragm , condom , tubal ligation , abstinence , monogamous relationship partner vasectomy ) ; 6 . Are judge good health base upon result physical examination , medical history , safety laboratory test ; 7 . Are willing able provide write informed consent ; 8 . Agree use wartremoving product ( prescription overthecounter [ OTC ] ) study product course study ; 9 . Are willing able comply requirement study ; 10 . Are free systemic dermatologic disorder , , opinion investigator , interfere study result increase risk AEs . 11 . Are willing refrain use cosmetic topical product treatment area duration study . 1 . Have less 2 10 common wart within designate treatment area ; 2 . Have wart outside treatment area would interfere study procedure analyse ; 3 . Have participate investigational trial within 30 day prior enrollment ; 4 . Have participate prior trial investigate EISO use treatment common wart ; 5 . Have use salicylic acid overthecounter wartremoving product treatment area within 30 day prior enrollment ; 6 . Have use use oral zinc and/or cimetidine within 30 day prior enrollment course study ; 7 . Have receive cryotherapy treatment area within 60 day prior enrollment ; 8 . Have require require systemic intake immunosuppressive immunomodulatory medication ( include oral parenteral corticosteroid ) within 30 day prior enrollment course study . Routine use inhale intranasal corticosteroid study allow ; 9 . Have current and/or recurrent pathologically relevant skin infection treatment area common wart ( exception Herpes simplex virus labialis ) ; 10 . Have current uncontrolled infection ; 11 . Are pregnant , plan become pregnant , breastfeed ; 12 . Have know sensitivity constituent investigational control product include sandalwood oil , fragrance , member Compositae family vascular plant ( eg , sunflower , daisy , dahlia , etc . ) ; 13 . Have chronic acute medical condition , opinion investigator , may interfere study result place subject undue risk ( include human immunodeficiency virus , systemic lupus erythematosis , viral hepatitis , etc . ) ; 14 . Have active malignancy undergo treatment malignancy nonmelanoma skin cancer ; 15 . Have , opinion investigator , clinically significant clinical laboratory result time screen may interfere study result place subject undue risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Verruca vulgaris</keyword>
</DOC>